Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Go back to Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia| (NASDAQ: AMLX) | Delayed: 16.28 +0.61 (3.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.67 | 52 Week High | $ | |||
| Open | $15.91 | 52 Week Low | $ | |||
| Day High | $16.38 | P/E | N/A | |||
| Day Low | $15.73 | EPS | $ | |||
| Volume | 1,375,323 | |||||
